Timothy P. Lynch - 19 Aug 2026 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Reporting relationship: 10%+ Owner
Issuer ticker: AEON
Reported as of: 19 Aug 2026
Net transaction value: +$243,455
SEC form: 4
Accepted by SEC: 21 Aug 2026, 19:41:07 UTC
Source filing: View source filing
Reporting owner signature: /s/ Timothy P. Lynch

Key filing fact

Timothy P. Lynch filed Form 4 for AEON Biopharma, Inc. (AEON) on 21 Aug 2026.

Key facts

This page summarizes Timothy P. Lynch's Form 4 filing for AEON Biopharma, Inc. (AEON).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Aug 2026, 19:41.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$243,455.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001270925 Primary reporting owner

LYNCH TIMOTHY P

Relationship: 10%+ Owner
Address: 70 SW CENTURY DR., STE. 100, BEND
Signature: /s/ Timothy P. Lynch
Signature date: 21 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AEON transaction

Class A Common Stock

Purchase

Transaction value: $243,455
Shares: +1,150,000
Change %: +21%
Price: $0.2117
Shares after: 6,500,000
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.